Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20510001 | 0.81 | LMNA (0.52) | MAOBNR4A2KMT2AP4HTMMEN1 | |
| SCHEMBL11617562 | 0.81 | P4HTM (0.60) | MAOBALOX5NR4A2KMT2AP4HTM | |
| SCHEMBL3735815 | 0.81 | CLK1 (0.48) | KMT2AMEN1KDM4EALDH1A1PKM | |
| SCHEMBL569919 | 0.81 | P4HTM (0.66) | MAOBALOX5NR4A2LTB4RLTB4R2 | |
| SCHEMBL30678236 | 0.79 | MAOB (0.66) | MAOBNR4A2KMT2AMEN1SRD5A2 | |
| SCHEMBL4200015 | 0.79 | MAOB (0.66) | MAOBNR4A2KMT2AMEN1SRD5A2 | |
| SCHEMBL23488362 | 0.78 | PARP10 (0.56) | MAOBNR4A2KMT2AP4HTMMEN1 | |
| SCHEMBL2713772 | 0.78 | CYP2C9 (0.41) | KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL18681644 | 0.77 | CSF1R (0.54) | MAOBNR4A2KMT2AP4HTMMEN1 | |
| SCHEMBL1034311 | 0.77 | MAOB (0.63) | MAOBALOX5NR4A2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3497098-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
| WO-2018031877-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018031877-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, FOLH1 | MAOB 275/4885ALOX5 493/4885NR4A2 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.